ClinicalTrials.gg
Sign In
Status unknownNCT05298761Updated Nov 21, 2023

Efficacy of I/v Nalbuphine v/s Iv Lignocain in Attanuation of Pressor Responseduring Laryngeoscopy and Intubation in Middle Age Patient Planned for Thyroid Surgery

An Early Phase 1 interventional study of Lignocaine in Hemodynamic Stability, sponsored by Sheikh Zayed Medical College. Status unknown at 1 site in Pakistan. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by Sheikh Zayed Medical College · Early Phase 1, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Nov 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Comparison of I/V nalbuphine versus I/V xylocain in attanuation of pressor response during intubation and laryngeoscopy in patients undergoing for thyroid surgery,selection of better supressor agent minimises the drug repated side effects like hypertention tachycardia but also helps in heamodynamically stability at induction.

02

Conditions studied

  • Hemodynamic Stability
03

In context

Lead sponsor

Sheikh Zayed Medical College is the lead sponsor of 27 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • middle age(18_40)
  • Asa 1 and 2
  • Non hypertensive
  • Thyroid patients
  • patient who gives consent

Exclusion criteria

Exclusion Criteria:

  • hypertensive
  • Asa 3 and 4
  • Patient refusal
05

Study design

Phase
Early Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Lignocain

    I/V lignocain 1.5mg per kg given to participants in state dose

    Drug: Lignocaine

  • Experimental
    nalbuphine

    I/v nalbuphine 0.1mg per kg given to participants in stat dose

    Drug: Lignocaine

Interventions

  • DrugLignocaine

    Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs

    Also known as: Nalbuphine

06

What researchers measure

Primary outcomes

  1. Reduce stress response during intubation and hemodynamic stabilty

    Assesment of Hemodynamic stability by observing vital signs

    Time frame: 10 minutes

  2. Achieve hemodynamic stabilty and smooth intubation

    Assesment of hemodynamic stability by clinical examination of vital signs

    Time frame: 10 minutes

07

Study locations

1 site
  • Dr.amna
    Rahim Yar Khan, Punjab Province 092, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2023; primary completion for Mar 2024, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Mar 28, 2022
StartEst.
Dec 30, 2023
Primary completionEst.
Mar 1, 2024
CompletionEst.
Jun 1, 2024
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05298761
Lead sponsor
Sheikh Zayed Medical College
Responsible party
Amna Sarwar (Principle investigator, Sheikh Zayed Medical College) — Principal investigator
First posted
Mar 28, 2022
Start date
Dec 30, 2023 (estimated)
Primary completion
Mar 1, 2024 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
Nov 21, 2023

Study contacts

Dr.amna Sarwar, Fcps
Contact
Dr.amnasabir@gmail.com
03218337129
Dr.amna Sarwar, Fcps
principal investigator · Sheikh zaied medical hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Other studies from this sponsor

Sheikh Zayed Medical College

Start the discussion